Valeo Pharma (VPH.C) is a specialty pharmaceutical company, engages in the acquisition, in-licensing, and commercialization of pharmaceutical products with a primary focus on neurodegenerative diseases, oncology and supportive care,…
Search Results for: VPH.C – Page 2
Valeo Pharma (VPH.C) announced today that it has completed implementation of its new corporate structure and launched full commercial activities in support of Enerzair Breezhaler triple therapy and Atectura…
I am writing about Valeo Pharma Inc. at a very fascinating time for biotech/health stocks. Recently, Biotech has been hot! Led by the vaccine companies which are soaring. Just…
Steve Saviuk, president and CEO of Valeo Pharma (VPH.C), talks about the transformative partnerships with international players such as Novartis and members of the Canadian Healthcare Industry, that allow…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
There’s nothing more terrifying than watching a loved one pause, clutch their throat and start gasping for air. The first time it happens provokes the mad scramble, as she…
Valeo Pharma’s (VPH.C) low molecular weight heparin (LMWH) drug, Redesca and Redesca HP, is now eligible for public reimbursement in seven provinces and territories across Canada, as well as…
Valeo Pharma (VPH.C) announced that they have begun commercialization of their Enerzair Breezhaler and Atectura Breezhaler following the shipment of the product across Canada and the deployment of their…
Anyone else watching charts trend downwards? Yeah. There’s a reason that junior market traders hold tight to the saying of “May: sell and go away”, but ‘May’ started unusually…